FDA-cleared profile

DEEPVESSEL Plaque

Keya Medical Technology Co., Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Coronary plaque and stenosis quantification from CCTA

Clinical role
Measurement, quantification and diagnostic support
Images and patients
CT/CTA · Heart/Cardiovascular
Key limitation
Keep in mind: Qualified clinician review and analyst correction are required. Interpolated views may appear healthy where pathology is near or below scanning resolution.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Coronary plaque and stenosis quantification from CCTA
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart/Cardiovascular Input: CCTA DICOM acquired on CT systems with at least 64 detector rows
  • Who uses it?Intended users: Qualified clinicians and trained analysts/operators
  • What does the software produce?Output: Vessel/lumen/wall segmentations; total, calcified, non-calcified and low-density plaque volumes/burden; stenosis measures; CAD-RADS category; Cardisight Overview and Plaque Analysis reports
  • What is its most important limitation?Key limitation: Qualified clinician review and analyst correction are required. Interpolated views may appear healthy where pathology is near or below scanning resolution.

Clinical takeaway. Clinical role: Coronary plaque and stenosis quantification from CCTA

Evidence takeaway. Evidence from the reviewed source record: Standalone study used 147 CCTA cases from three US sites with three-expert consensus reference; it did not use IVUS or histology as reference.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Coronary plaque and stenosis quantification from CCTA
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Measurement, quantification and diagnostic support
  • Exact FDA submission
  • Checked 2026-09-05
Required input
CCTA DICOM acquired on CT systems with at least 64 detector rows
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
Vessel/lumen/wall segmentations; total, calcified, non-calcified and low-density plaque volumes/burden; stenosis measures; CAD-RADS category; Cardisight Overview and Plaque Analysis reports
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Adults age 22 and older with known or suspected coronary artery disease
  • Exact FDA submission
  • Checked 2026-09-05
Intended users
Qualified clinicians and trained analysts/operators
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
Qualified clinician review and analyst correction are required. Interpolated views may appear healthy where pathology is near or below scanning resolution.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
Standalone study used 147 CCTA cases from three US sites with three-expert consensus reference; it did not use IVUS or histology as reference.
  • Exact FDA submission
  • Checked 2026-09-05

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Standalone study used 147 CCTA cases from three US sites with three-expert consensus reference; it did not use IVUS or histology as reference.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No clinically interpretable sensitivity estimate was established in the reviewed summary.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No clinically interpretable specificity estimate was established in the reviewed summary.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K260497 CCTA plaque/stenosis study

  • DesignStandalone expert-reference comparison
  • PopulationCCTA cases from three US sites
  • Scopeexact submission
  • Tested versionDEEPVESSEL Plaque in K260497
  • Samplen=147
  • Sites3
  • IndependenceIndependence not established

K260497

Reference is three-expert consensus, not IVUS or histology.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

Reimbursement
Medicare local coverage policy L39881 (Noridian, MAC jurisdictions J-E and J-F) covers AI-enabled coronary plaque analysis from an already completed and interpreted CCTA for stable or acute chest pain with no known coronary disease when the CCTA is intermediate risk or CAD-RADS 1 to 3 and acute coronary syndrome evaluation is negative or inconclusive. It requires FDA cleared or approved software and does not name any product. The related billing article lists CPT 75577 (added effective 2026-01-01, replacing Category III codes 0623T-0626T). This is a regional service-level policy, not a determination that this exact product, version, site or claim is covered or paid. No payment amount was reviewed.
  • Service-level, not product-specific
  • Checked 2026-10-25

75577

Service-level local coverage policy found (Noridian JE/JF LCD L39881); product-specific coverage and payment not established

Medicare (Noridian Healthcare Solutions MACs, jurisdictions J-E and J-F) · Noridian JE and JF states (California, Nevada, Hawaii, American Samoa, Guam, Northern Mariana Islands, Alaska, Arizona, Idaho, Montana, North Dakota, Oregon, South Dakota, Utah, Washington, Wyoming); other MAC jurisdictions not reviewed · Effective 2026-01-01

Code effective date comes from the billing article revision. LCD requires FDA cleared or approved software but names no product. Does not prove eligibility for a particular product version, patient, indication, site or claim; no payment amount reviewed.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: CCTA DICOM acquired on CT systems with at least 64 detector rows

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · DEEPVESSEL Plaque: K260497 decision and 510(k) summary

  2. Routing

    Source context, not route validation: Web-based workflow with secure PACS data transfer described in FDA review

    Scope: Exact FDA submission. This data-flow description is not a current security certification.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · DEEPVESSEL Plaque: K260497 decision and 510(k) summary

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Hosting region, retention, supported PACS interfaces and purchased configuration were not established.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 ·

  4. Returned objects

    Source context, not route validation: Vessel/lumen/wall segmentations; total, calcified, non-calcified and low-density plaque volumes/burden; stenosis measures; CAD-RADS category; Cardisight Overview and Plaque Analysis reports

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · DEEPVESSEL Plaque: K260497 decision and 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: Vessel/lumen/wall segmentations; total, calcified, non-calcified and low-density plaque volumes/burden; stenosis measures; CAD-RADS category; Cardisight Overview and Plaque Analysis reports

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · DEEPVESSEL Plaque: K260497 decision and 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Web-based workflow with secure PACS data transfer described in FDA review
  • Exact FDA submission
  • Checked 2026-09-05

This data-flow description is not a current security certification.

Current product-family reporting

Vendor describes analyst review and two plaque-analysis reports.

product family · checked 2026-09-05

Separate FFR features are not attributed to DEEPVESSEL Plaque.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K260497
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-06-04
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-06Last searched
20Fields reviewed
11Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored PubMed and clinical-trial candidate arrays are empty and were screened. No study was fabricated from vendor validation material. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision summary, vendor product page, literature index, trial registry, recall database, payer policy, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission

    No public exact-version rate or procurement award reviewed.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not verified - checked 2026-09-05 - Exact FDA submission

    Hosting region, retention, supported PACS interfaces and purchased configuration were not established.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-05 - Exact FDA submission

    No dated, scoped security attestation reviewed.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-05 - Exact FDA submission

    Analyst credentialing, correction workflow and cardiologist review protocol require confirmation.

  • Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission

    Reanalysis turnaround and analyst correction audit processes need local confirmation.

10 sources - 3 history items

Source ledger

  1. K260497 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. DEEPVESSEL Plaque model card (K260497)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. DEEPVESSEL Plaque: K260497 decision and 510(k) summary

    U.S. Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinical, evidence, implementation

  8. DEEPVESSEL Plaque

    Keya Medical - Accessed 2026-09-05

    Scope: implementation

  9. CMS Medicare Coverage Database LCD L39881: Artificial Intelligence Enabled CT Based Quantitative Coronary Topography (AI-QCT)/Coronary Plaque Analysis (AI-CPA)

    Noridian Healthcare Solutions (MAC jurisdictions J-E and J-F), via CMS Medicare Coverage Database - Accessed 2026-10-25

    Scope: reimbursement, coding, payerPolicy

  10. CMS Medicare Coverage Database Billing and Coding Article A59769: AI-QCT/AI-CPA

    Noridian Healthcare Solutions (MAC jurisdictions J-E and J-F), via CMS Medicare Coverage Database - Accessed 2026-10-25

    Scope: reimbursement, coding, payerPolicy

Research history

  1. K260497 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252217

CT VScore+

Canon Medical Informatics, Inc.

Authorized purpose: CT VScore+ evaluates calcified coronary lesions on ECG-gated, non-contrast cardiac CT in patients aged 30 years or older, automatically generating coronary calcium scores and highlighted calcium segmentation for qualified clinical review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-11-28
FDA-cleared K251027

cvi42 Coronary Plaque Software Application

Circle Cardiovascular Imaging, Inc.

Authorized purpose: cvi42 Coronary Plaque supports qualified professionals with viewing, post-processing, and qualitative and quantitative evaluation of adult cardiac CT DICOM images to assess the presence and extent of coronary plaques and stenoses in CCTA for CAD or suspected CAD.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-10-27
FDA-cleared K251656

Careverse CoronaryDoc (Careverse CoronaryDoc)

Careverse Technology Pte. Ltd.

Authorized purpose: Careverse CoronaryDoc is a web-based tool for trained medical professionals to view and analyze CCTA CT data for coronary plaques and stenosis, with coronary measurements, visualization, automated plaque and stenosis outputs, and structured reporting for physician review.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-09-04
FDA-cleared K243859

PRAEVAorta®2

Nurea

Authorized purpose: PRAEVAorta 2 assists clinical specialists, physicians, and other licensed practitioners with automatic vascular segmentation and maximum-diameter measurement on adult CT images; results require clinical assessment and physician validation when obtained by a non-physician.

Modality
CT/CTA
Anatomy
Heart/Cardiovascular
Decision
2025-08-29

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history